Researchers track Body's response to lifesaving fat disorder drug
NCT ID NCT04026178
Summary
This study monitored 11 patients with generalized lipodystrophy, a rare disorder causing severe fat loss and metabolic problems, who were starting daily metreleptin injections. The main goal was to see if their immune systems developed antibodies against the drug over three years and to check for any related safety issues. This was a required follow-up study after the drug was approved to ensure its long-term safety profile.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Endocrinology Research Associates
Columbus, Ohio, 43201, United States
-
Ochsner Clinic
New Orleans, Louisiana, 70121, United States
-
Ohio State University
Columbus, Ohio, 43203, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
Univ. Alabama-Birmingham
Birmingham, Alabama, 35294, United States
-
University Texas Southwestern INT
Dallas, Texas, 75390, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.